VIRGINIA KNIGHT: Open Payments
NPI 1770946048 · SAINT MARYS, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$644 in 33 payments from 17 companies in 2025. Trend: 2023 $33 · 2024 $233 · 2025 $644
Food & beverage: $644
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 6 | $113 |
| Novartis Pharmaceuticals Corporation | 3 | $73 |
| Otsuka America Pharmaceutical, Inc. | 4 | $72 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $64 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $41 |
| Novo Nordisk Inc | 2 | $38 |
| GlaxoSmithKline, LLC. | 2 | $36 |
| Phathom Pharmaceuticals, Inc. | 1 | $25 |
| Almatica Pharma LLC | 1 | $24 |
| Lilly USA, LLC | 1 | $22 |
Products named: Veozah, LEQVIO, REXULTI, XIFAXAN, Kerendia, VOQUEZNA, TERIPARATIDE, Wegovy.
Industry payments across GA — which companies pay providers there.
